- Home
- POR vs APGE Comparison
POR vs APGE Comparison
Compare POR & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | POR | APGE |
|---|---|---|
| Founded | 1889 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.7B |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | POR | APGE |
|---|---|---|
| Price | $48.62 | $76.65 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 7 |
| Target Price | $46.27 | ★ $99.57 |
| AVG Volume (30 Days) | ★ 1.3M | 752.2K |
| Earning Date | 10-31-2025 | 11-10-2025 |
| Dividend Yield | ★ 4.32% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.78 | N/A |
| Revenue | ★ $3,511,000,000.00 | N/A |
| Revenue This Year | $5.15 | N/A |
| Revenue Next Year | $4.73 | N/A |
| P/E Ratio | $17.50 | ★ N/A |
| Revenue Growth | ★ 5.09 | N/A |
| 52 Week Low | $39.55 | $26.20 |
| 52 Week High | $51.14 | $77.09 |
Technical Indicators
Market Signals| Indicator | POR | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 49.63 | 77.15 |
| Support Level | $49.06 | $67.68 |
| Resistance Level | $51.14 | $73.90 |
| Average True Range (ATR) | 0.73 | 3.41 |
| MACD | -0.32 | 0.51 |
| Stochastic Oscillator | 8.01 | 96.82 |
Price Performance
Historical ComparisonAbout POR Portland General Electric Co
Portland General Electric is a regulated electric utility providing generation, transmission, and distribution services in a service territory that includes about half of all Oregon residents and two-thirds of the state's business activity. The company owns (wholly or through joint ventures) 3.5 gigawatts of gas, coal, wind, and hydro generation along with 100 megawatts of energy storage.
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.